FTC remedy for Aurobindo–Lannett generic-drug merger heads to public comments

The Federal Trade Commission (FTC) is moving the Aurobindo–Lannett generic-drug merger through an enforcement step that includes a proposed consent-order remedy. On June 18, 2026, the FTC announced a remedy that hinges on divesting four specified generic drug products to Quagen Pharmaceuticals.

Because the order is proposed, it is not final yet. It is subject to a federal public-comment process before the FTC can finalize the consent order.

What the FTC announced on June 18, 2026

In its June 18, 2026 action, the FTC said it is taking steps to protect Americans from higher drug costs that could result if competition is reduced in certain U.S. generic-drug markets tied to the merger.

The competitive concern: specific generic markets

The FTC’s complaint materials explain the agency’s competition concerns in relevant product markets for the generic drugs covered by its legal challenge. The FTC frames the risk as a potential shift in bargaining power when fewer competitors remain, which can affect pricing and access.

What the proposed remedy requires: divestitures to Quagen

The remedy centers on divestiture of four specified generic drug products to Quagen. The FTC’s decision/order materials define the exact product scope—this is not a broad, “any similar drug” requirement.

The documents also describe compliance and monitoring mechanics, meaning the FTC intends oversight to ensure the divestiture and related obligations occur as required.

The Federal Register step: comments on a proposed consent order

On June 23, 2026, the Federal Register published an “Analysis of Proposed Consent Orders” notice for this matter. For readers, the key point is that the remedy is still in the proposal-and-review stage, not already final.

The key deadline: comments due July 23, 2026

The notice states that the public-comment period ends on July 23, 2026. After that date, the FTC can consider the record and move toward finalizing the consent order.

What to watch next (why it matters for household budgets)

The consumer stake is straightforward: generic-drug competition can influence pricing and availability. What to watch next includes:

• Whether the consent order is finalized after the comment period closes.
• Whether the required divestitures are executed under the order’s defined product scope and timeline structure.
• Compliance and monitoring milestones the FTC lays out in the decision/order materials.

Until the order is finalized and the divestiture obligations are carried out, the FTC’s arguments about competitive harm should be read as part of its legal remedy framework—not as an already-proven, one-to-one prediction of specific price changes for every consumer.

Sources

• FTC Press Release (June 18, 2026): FTC takes action to protect Americans from higher drug costs in Aurobindo–Lannett deal (proposed remedy/divestitures)
• FTC Decision and Order (Aurobindo–Lannett): Proposed consent order remedy document (divestiture/compliance details)
• Federal Register (June 23, 2026): Analysis of Proposed Consent Orders (Aurobindo–Lannett) + public comment deadline